Clinical Trials
3,721 trialsNCT00932412 2026-05-27
CLARA
Hospices Civils de Lyon
Phase 2 Completed
NCT01774630 2026-05-26
NiloPost-STIM
University Hospital, Bordeaux
Phase 2 Completed
NCT03434730 2026-05-26
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04088864 2026-05-26
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
Phase 1 Completed
NCT01190930 2026-05-22
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT04915612 2026-05-20
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05534620 2026-05-20
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
Phase 1 Completed
NCT01343173 2026-05-19
STIM 2
University Hospital, Bordeaux
Phase NA Completed
NCT05564650 2026-05-19
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Completed
NCT04742101 2026-05-18
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Phase 1/2 Completed
NCT02993523 2026-05-15
Viale-a
AbbVie
Phase 3 Completed
NCT03600155 2026-05-15
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03900949 2026-05-15
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02362035 2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT04687761 2026-05-13
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
PETHEMA Foundation
Phase 1/2 Completed
NCT06649006 2026-05-13
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Phase 1 Completed
NCT04205409 2026-05-12
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Phase 2 Completed
NCT05335369 2026-05-11
UR-GOAL 2
University of Rochester
Phase NA Completed
NCT05460013 2026-05-11
Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation
RenJi Hospital
Phase NA Completed
NCT03413800 2026-05-08
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Ciusss de L'Est de l'Île de Montréal
Phase 2 Completed
NCT05490121 2026-05-08
RISE Residents
McMaster University
Phase NA Completed
NCT00720785 2026-05-07
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02300961 2026-05-07
Feasibility Neurocognitive Outcome After Transplant
Stanford University
Phase NA Completed
NCT05155709 2026-05-07
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis
Phase 1 Completed
NCT04745910 2026-05-06
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 4 Completed
NCT05532722 2026-05-06
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Abcuro, Inc.
Phase 1/2 Completed
NCT05829226 2026-05-06
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
Phase 1 Completed
NCT05441514 2026-05-05
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Completed
NCT00641381 2026-05-04
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT01087294 2026-05-04
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03035331 2026-05-04
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT04509765 2026-05-04
A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT
NYU Langone Health
Phase NA Completed
NCT04167917 2026-05-01
NTX-301 in MDS/AML
University of Alabama at Birmingham
Phase 1 Completed
NCT01231412 2026-04-30
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT00558519 2026-04-29
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT04819854 2026-04-29
Single and Multiple Ascending Dose Study With EP395
EpiEndo Pharmaceuticals
Phase 1 Completed
NCT02315612 2026-04-28
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03068819 2026-04-24
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
Washington University School of Medicine
Phase 1/2 Completed
NCT03580655 2026-04-24
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT05388123 2026-04-24
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Scripps Health
Phase 2 Completed
NCT01279096 2026-04-22
Vandevol
University Hospital, Lille
Phase 1 Completed
NCT03009240 2026-04-22
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Completed
NCT01853358 2026-04-21
DLI-NK
Institut Paoli-Calmettes
Phase 1 Completed
NCT02553447 2026-04-21
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
University of Nebraska
Phase NA Completed
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT05858593 2026-04-21
Positive Youth Development in the Metaverse
University of Georgia
Phase NA Completed
NCT04625413 2026-04-20
UR-GOAL 1
University of Rochester
Phase NA Completed
NCT04996160 2026-04-17
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Completed
NCT05282459 2026-04-17
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
NCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed